A method of preparing a glycol mono-ether or mono-acetate, or carbonate involving either one of two pathways from alkylene glycols, HMF or its reduction derivative products (i.e., FDM, bHMTHFs), is provided. In particular, according to one pathway, the alkylene glycol, HMF or FDM, bHMTHFs are reacted with a dialkyl carbonate in the presence of a deprotonating agent, in substantial absence of an extrinsic catalyst, to produce an ether, and subsequently reacting the ether with an acid base. According to the other pathway, alkylene glycols are reacted with an acetate donor in the presence of an acid, base, to generate an alkylene monoacetate, and etherified with a carbonate in the presence of a deprotonating agent.

A method of preparing a glycol mono-ether or mono-acetate, or carbonate involving either one of two pathways from alkylene glycols, HMF or its reduction derivative products (i.e., FDM, bHMTHFs), is provided. In particular, according to one pathway, the alkylene glycol, HMF or FDM, bHMTHFs are reacted with a dialkyl carbonate in the presence of a deprotonating agent, in substantial absence of an extrinsic catalyst, to produce an ether, and subsequently reacting the ether with an acid base. According to the other pathway, alkylene glycols are reacted with an acetate donor in the presence of an acid, base, to generate an alkylene monoacetate, and etherified with a carbonate in the presence of a deprotonating agent.

A facile, straightforward method for alkylation of anhydrosugar alcohols (isohexides) using a carbonate reagent is described. The alkylation method involves: a) contacting in a solution of an isohexide with a dialkyl, diallyl, or diaryl carbonate, and the solution includes a Brnsted base; and b) producing either an alkyl ether or alkyl carbonate of the isohexide compound. The alkylation reaction is in situ, that is, performed without an extrinsic catalyst. According to the method, one can synthesize various ethers and carbonates.

The original abstract is amended to A carbonate-containing unsaturated compound and a preparation method for a carbonate-containing unsaturated compound, a cured product and a method for degrading a cured product are provided. The carbonate-containing unsaturated compound includes a structure represented by formula (I) or formula (II). Formula (I) and formula (II) are defined as in the specification.

The original abstract is amended to A carbonate-containing unsaturated compound and a preparation method for a carbonate-containing unsaturated compound, a cured product and a method for degrading a cured product are provided. The carbonate-containing unsaturated compound includes a structure represented by formula (I) or formula (II). Formula (I) and formula (II) are defined as in the specification.

A process prepares glycerol carbonate (meth)acrylate by transesterification of methyl (meth)acrylate with glycerol carbonate, in the presence of a zirconium acetylacetonate catalyst. The catalyst is pretreated with 2% by weight to 25% by weight of water, based on the amount of catalyst.

A process prepares glycerol carbonate (meth)acrylate by transesterification of methyl (meth)acrylate with glycerol carbonate, in the presence of a zirconium acetylacetonate catalyst. The catalyst is pretreated with 2% by weight to 25% by weight of water, based on the amount of catalyst.

The present specification relates to a method for preparing an asymmetric linear carbonate.

The present specification relates to a method for preparing an asymmetric linear carbonate.

The application related to an ibuprofen ester derivative and an emulsion preparation thereof. A carboxyl group of racemic ibuprofen or S-ibuprofen is derivatized so that Compound N9 and a dextrorotatory enantiomer N9(S) thereof are obtained and further prepared into an emulsion preparation, which overcomes the problems of safety and compliance of patients existing in clinical application of existing ibuprofen/dexibuprofen injections and achieves the purposes of reducing vascular irritation, increasing clinical use approaches, and improving the stability of preparations in clinical applications.